Transmutex

Transmutex is a Swiss engineering company that designs technology and software for accelerator-powered nuclear systems. According to its official website, the company is developing an entirely new technology applicable to nuclear energy, nuclear waste and nuclear medicine. Its stated mission is to reinvent nuclear energy, waste and medicine by using a proton accelerator to transmute existing nuclear waste into clean energy while also producing radioisotopes for medical and industrial applications. The company describes three main areas of application. In energy, Transmutex says its technology generates energy that can be used as district heat or electricity, with safety, proliferation resistance and environmental sustainability. In waste management, it presents a solution that drastically reduces the volume and radiotoxicity of long-lived nuclear waste; material that would otherwise persist for hundreds of thousands of years could, with its technology, decay in less than 500 years, transforming the requirements for deep geological storage. In medicine, Transmutex aims to revolutionize cancer diagnosis and treatment through advanced production and development of radioactive isotopes, extracting these elements from nuclear waste or directly producing them with its proton accelerator. The company presents itself as working in proud collaboration with partners and backed by tier-one investors and private investors. Its board of directors includes Franklin Servan-Schreiber as Chairman, with Hendrik Höfer, Helen Lin, Jean-Christophe de Mestral, Victoire Newman and Cameron Porter as directors, and Daniel Bertholet and Brian Steinberg as observers. Transmutex is privately held and is based in Switzerland. It operates at the intersection of nuclear engineering, energy systems, waste transmutation and nuclear medicine, positioning itself as an innovator in sustainable energy and healthcare technology.

Transmutex is a Swiss accelerator-based nuclear technology company. Public information about its early corporate history is limited, but its official website describes an engineering company producing designs and software for an accelerator-powered technology that turns existing nuclear waste into clean energy and produces radioisotopes for medical and industrial applications. The company presents its work as being carried out in proud collaboration with partners and supported by tier-one investors and private investors. The company's technology concept centers on using a proton accelerator to drive nuclear transmutation. According to its website, this approach has three areas of application. First, energy: Transmutex generates energy to be used as district heat or as electricity, with safety, proliferation resistance and environmental sustainability. Second, waste: the company presents a solution that drastically reduces the volume and radiotoxicity of long-lived nuclear waste, so that waste which would otherwise persist for hundreds of thousands of years can decay in less than 500 years, transforming the requirements for deep geological storage. Third, medicine: Transmutex aims to revolutionize cancer diagnosis and treatment through advanced production and development of radioactive isotopes, extracting these elements from nuclear waste or directly producing them with its proton accelerator. As of the available evidence, Transmutex is privately held and based in Switzerland. Its board of directors includes Franklin Servan-Schreiber as Chairman, with Hendrik Höfer, Helen Lin, Jean-Christophe de Mestral, Victoire Newman and Cameron Porter as directors, and Daniel Bertholet and Brian Steinberg as observers. The company positions itself as an innovator in sustainable energy and nuclear medicine, operating at the intersection of nuclear engineering, energy systems, waste transmutation and healthcare technology.

Innovators in sustainable energy, developing accelerator-powered nuclear technology for energy, waste reduction and nuclear medicine.

• Accelerator-powered nuclear energy system

  Generates energy for district heat or electricity with safety, proliferation resistance and environmental sustainability.

• Nuclear waste transmutation solution

  Drastically reduces volume and radiotoxicity of long-lived nuclear waste, allowing decay in less than 500 years.

• Medical radioisotope production

  Produces radioactive isotopes from nuclear waste or directly with a proton accelerator for cancer diagnosis and treatment.

1. 1Transmutex | Innovators in Sustainable Energytransmutex.com
2. 2Transmutex - Wikidatawikidata.org